Compass Therapeutics, Inc.CMPXEarnings & Financial Report

Nasdaq · pharmaceutical industry

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).

NextMar 30, 2026

Revenue

Gross Profit

N/A

Operating Profit

$-15.8M

Net Profit

$-14.3M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.08

Compass Therapeutics, Inc. Q3 2025 Financial Summary

Compass Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-14.3M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.